LabCorp Launches New Patient-Centric Diabetes Report

BURLINGTON, N.C. --(BUSINESS WIRE)--Feb. 10, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the availability of a new Diabetes Patient Education report for type 2 diabetes patients that aligns with the American Diabetes Association (Association)

LabCorp Prices $500,000,000 in 2.625% Senior Notes Due 2020, $500,000,000 in 3.200% Senior Notes Due 2022, $1,000,000,000 in 3.600% Senior Notes Due 2025 and $900,000,000 in 4.700% Senior Notes Due 2045

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 21, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that it has priced its offering of $2.9 billion in senior notes. The offering consists of four tranches: $500,000,000 aggregate principal amount of 2.625% Senior

LabCorp Announces Proposed Sale of Senior Notes

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 21, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in four tranches with maturities of 5,7,10 and 30

LabCorp is Scheduled to Present at the 33rd Annual J.P. Morgan Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 6, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that David P. King , Chairman and Chief Executive Officer, is scheduled to speak at the 33 rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 2, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Introduces a Test to Identify Enterovirus D-68 (EV-D68)

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 18, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the availability of a reflex test to identify enterovirus D68 (EV-D68), which is associated with severe respiratory illness that primarily affects children.

LabCorp Named Laboratory Service Provider of the Pro Football Legends

MOUNT LAUREL, N.J. & BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 17, 2014-- Pro Football Legends, the commercial marketing arm of the National Football League Alumni, Inc. (NFL Alumni) and Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) are pleased to announce that they have

Hart-Scott-Rodino Waiting Period Expires for LabCorp Acquisition of Covance

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 16, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) and Covance Inc. ( Covance ) (NYSE: CVD) jointly announced today the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act,

LabCorp Announces Acquisition of Bode Technology

Acquisition expands LabCorp’s forensic DNA testing and relationship analysis capabilities BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 5, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced the completion of its acquisition of Bode Technology Group, Inc.

LabCorp Completes Acquisition of LIPOSCIENCE

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 21, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced the completion of its acquisition of LIPOSCIENCE, Inc. (NASDAQ:LPDX), effective November 20, 2014 . At a special meeting held on November 20, 2014 , LIPOSCIENCE’s